Li Juan, Luo Shaokai, Hong Wende, Zhou Zhenhai, Zou Waiyi
Department of Hematology, First Hospital, Sun Yet-Sen Medical University, Guangzhou 510080, China.
Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):254-6.
To evaluate the mechanism and influence of thalidomide on interleukin-6 (IL-6), IL-6 receptor (IL-6R) and its transmitting chain in multiple myeloma patients.
Serum level of IL-6, expression of IL-6R on myeloma cells and IL-6R beta mRNA in multiple myeloma patients were measured by enzyme linked immunosorbent assay (Elisa), flow cytometry and reverse transcription polymerase chain reaction (RT-PCR).
Serum level of IL-6 in multiple myeloma patients was 564.8 +/- 319.4 ng/L, with a positive rate on the myeloma cells of 33.6% before oral 200 mg/d thalidomide. They were 560.3 +/- 414.8 ng/L and 31.8% on D14 after oral 200 mg/d thalidomide, which were not significantly different as compared with those before (P > 0.05). On D14, 28, 42, 56 and 84 after oral 400 mg/d thalidomide, the serum level of IL-6 in multiple myeloma patients were 516.7 +/- 131.9 ng/L, 426.7 +/- 180.4 ng/L, 387.9 +/- 187.4 ng/L, 350.1 +/- 85.5 ng/L and 212.3 +/- 92.5 mg/L, with positive rates on the myeloma cells of 28.5%, 24.3%, 21.3%, 12.6% and 10.1%, which were all lower than those before oral 200 mg/d thalidomide (P < 0.05 or P < 0.01). Ratios before and on D14 after oral 200 mg/d thalidomide were 7.8 and 6.9, with no statistical significance (P > 0.05). Ratios on D14, 28 after oral 400 mg/d thalidomide were 5.3 and 2.7, which were lower than those before oral 200 mg/d thalidomide (P < 0.01).
Reduction of serum level of IL-6 in multiple myeloma patients and decrease in IL-6R expression on the myeloma cells and IL-6R beta mRNA occur on D14 after oral 400 mg/d thalidomide. These changes become more obvious with time. The antitumor mechanism of thalidomide may be related to reduction of IL-6 serum level in multiple myeloma patients and decrease in IL-6R expression on the myeloma cells and IL-6R beta mRNA.
评估沙利度胺对多发性骨髓瘤患者白细胞介素-6（IL-6）、IL-6受体（IL-6R）及其传导链的作用机制和影响。
采用酶联免疫吸附测定（Elisa）、流式细胞术及逆转录聚合酶链反应（RT-PCR）检测多发性骨髓瘤患者血清IL-6水平、骨髓瘤细胞上IL-6R的表达及IL-6Rβ mRNA。
多发性骨髓瘤患者口服200mg/d沙利度胺前血清IL-6水平为564.8±319.4ng/L，骨髓瘤细胞阳性率为33.6%。口服200mg/d沙利度胺后第14天，血清IL-6水平为560.3±414.8ng/L，阳性率为31.8%，与口服前相比差异无统计学意义（P>0.05）。口服400mg/d沙利度胺后第14、28、42、56和84天，多发性骨髓瘤患者血清IL-6水平分别为516.7±131.9ng/L、426.7±180.4ng/L、387.9±187.4ng/L、350.1±85.5ng/L和212.3±92.5mg/L，骨髓瘤细胞阳性率分别为28.5%、24.3%、21.3%、12.6%和10.1%，均低于口服200mg/d沙利度胺前（P<0.05或P<0.01）。口服200mg/d沙利度胺前与第14天的比值分别为7.8和6.9，差异无统计学意义（P>0.05）。口服400mg/d沙利度胺后第14、28天的比值分别为5.3和2.7，低于口服200mg/d沙利度胺前（P<0.01）。
口服400mg/d沙利度胺后第14天，多发性骨髓瘤患者血清IL-6水平降低、骨髓瘤细胞上IL-6R表达及IL-6Rβ mRNA减少，且随时间变化更明显。沙利度胺的抗肿瘤机制可能与降低多发性骨髓瘤患者血清IL-6水平、减少骨髓瘤细胞上IL-6R表达及IL-6Rβ mRNA有关。
